Public health surveillance of cancer survival in the United States and worldwide: The contribution of the CONCORD programme

BACKGROUND Ovarian cancer is the fifth leading cause of cancer death among women in the United States. This study reports ovarian cancer survival by state, race, and stage at diagnosis using data from the CONCORD-2 study, the largest and most geographically comprehensive, population-based survival study to date. METHODS Data from women diagnosed with ovarian cancer between 2001 and 2009 from 37 states, covering 80% of the US population, were used in all analyses. Survival was estimated up to 5 years and was age standardized and adjusted for background mortality (net survival) using state-specific and race-specific life tables. RESULTS Among the 172,849 ovarian cancers diagnosed between 2001 and 2009, more than one-half were diagnosed at distant stage. Five-year net survival was 39.6% between 2001 and 2003 and 41% between 2004 and 2009. Black women had consistently worse survival compared with white women (29.6% from 2001–2003 and 31.1% from 2004–2009), despite similar stage distributions. Stage-specific survival for all races combined between 2004 and 2009 was 86.4% for localized stage, 60.9% for regional stage, and 27.4% for distant stage. CONCLUSIONS The current data demonstrate a large and persistent disparity in ovarian cancer survival among black women compared with white women in most states. Clinical and public health efforts that ensure all women who are diagnosed with ovarian cancer receive appropriate, guidelines-based treatment may help to decrease these disparities. Future research that focuses on the development of new methods or modalities to detect ovarian cancer at early stages, when survival is relatively high, will likely improve overall US ovarian cancer survival.

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Disparities in ovarian cancer survival in the United States (2001‐2009): Findings from the CONCORD‐2 study

Stewart

Harewood

Matz

et al. 2017

“…Population-based cancer survival differs in a fundamental way from the survival of patients with cancer who are participating in clinical trials. 25,26 Population-based survival reflects the average survival for all patients with cancer in the population, regardless of their age, sex, race, health status, stage of disease, socioeconomic position, residence at the time of diagnosis, and access to care. As such, population-based cancer survival provides an indicator of the overall effectiveness of the health care system to deliver screening, early diagnosis, and evidenced-based treatment services and follow-up care to all individuals in the population being served.…”

Section: Cancer Surveillance In the United Statesmentioning

confidence: 99%

“…Population‐based cancer survival differs in a fundamental way from the survival of patients with cancer who are participating in clinical trials . Population‐based survival reflects the average survival for all patients with cancer in the population, regardless of their age, sex, race, health status, stage of disease, socioeconomic position, residence at the time of diagnosis, and access to care.…”

Section: Introductionmentioning

confidence: 99%

Population‐based cancer survival (2001 to 2009) in the United States: Findings from the CONCORD‐2 study

Weir

Stewart

Allemani

et al. 2017

Self Cite

The Centers for Disease Control and Prevention helps to support a nationwide network of population‐based cancer registries that collect information regarding all patients diagnosed with cancer. These data tell a compelling story about the disproportionate burden of lower cancer survival experienced by vulnerable populations, and can be used by state and national partners to inform cancer control activities.

“…CONCORD is a program for the global surveillance of cancer survival. In 2015, the second cycle of the program (CONCORD‐2) established the long‐term surveillance of cancer survival worldwide . In this supplement to Cancer , net survival by race, stage at diagnosis, and state of residence at the time of diagnosis are presented for 10 commonly diagnosed cancers.…”

mentioning

confidence: 99%

The essential role of population‐based cancer survival in cancer control in the United States

Weir

Richardson

2017

This supplement benchmarks the status of population‐based survival for 10 leading cancers in the United States just prior to the implementation of the Patient Protection and Affordable Care Act. Overall survival in the United States is among the highest in the world; however, large racial disparities persist and health equity has been elusive. Further improvements in survival may be observed in the era of personalized cancer care and targeted therapies, and as federal and state initiatives seek to improve patient access to timely, effective therapies and care.